It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Using Index Funds In Retirement Portfolios discusses straightforward methods to blend broad-market index funds into retirement allocations.
18,590 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Apple has delivered outsized gains since Tim Cook took the helm. A $10,000 stake from that era would sit on a hefty b...
As the 2026 tax season approaches, a niche tactic tied to short-term rentals is drawing attention from investors and ...
The AI gold rush has turbocharged demand for specialized chips. Morgan Stanley warns of chipflation as hyperscalers i...
As AI investment surges, the real cash flow winners are the hardware and infrastructure suppliers. Analysts say forge...
As Oracle doubles down on AI, market dynamics and debt concerns push billionaire wealth into sharp focus. Analysts de...
AI-driven capital spending is set to surge, pushing capex crosses trillion next. Here are two industrial stocks—Verti...
Markets are sizing Coca-Cola for a two-year path as AI-driven capital shifts reshape sectors. A fresh price predictio...
Two space pioneers, two distinct paths to growth. This guide compares SpaceX Spacemobile and AST SpaceMobile, with pr...
When headlines scream spacex stock drop again, investors scramble for what really moved the price. This article break...
July markets showed a cautious tone as Ondas revealed a fresh $70 million order backlog. The stock jumped, while majo...
Blue (OBDC) 2025 earnings could signal how well the firm leverages private credit trends and cost discipline. This gu...